Article
Medicine, General & Internal
Dandan Mao, Huanyi Cao, Mai Shi, Chi Chiu Wang, Joseph Kwong, Joshua Jing Xi Li, Yong Hou, Xing Ming, Heung Man Lee, Xiao Yu Tian, Chun Kwok Wong, Elaine Chow, Alice Pik Shan Kong, Vivian Wai Yan Lui, Paul Kay Sheung Chan, Juliana Chung Ngor Chan
Summary: Our study revealed that the expression of PSMA2 and GLP-1R was increased and positively correlated in T2D-related cervical cancer specimens, suggesting hyperglycemia might promote cancer growth by increasing PSMA2 expression, which could be attenuated by Exendin-4.
Article
Medicine, Research & Experimental
Shimpei Iikuni, Ichiro Kamei, Takaki Ohara, Hiroyuki Watanabe, Masahiro Ono
Summary: A GLP-1R imaging probe [In-111]In-E4DA1 has been developed, which can detect the location of insulinomas in vivo and has reduced renal accumulation.
MOLECULAR PHARMACEUTICS
(2022)
Article
Biochemistry & Molecular Biology
Jufen Liu, Huijing Wang, Cuiting Huang
Summary: This study found that Exendin-4 has a protective effect in inhibiting the progression of DR, and it may exert its effect by regulating the expression of TGFB2.
ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY
(2023)
Article
Medicine, Research & Experimental
Shimpei Iikuni, Takaki Ohara, Hiroyuki Watanabe, Masahiro Ono
Summary: In this study, 111In-labeled exendin-4 derivatives with specific albumin binder (ALB) moieties were designed and synthesized for noninvasive detection of insulinomas. Through in vitro and in vivo experiments, it was determined that these derivatives exhibited good affinity and tumor accumulation, while showing lower renal accumulation. These results provide important guidance for the design of novel radioligands targeting GLP-1R.
MOLECULAR PHARMACEUTICS
(2022)
Article
Nutrition & Dietetics
Abrar Alnami, Abdulhadi Bima, Aliaa Alamoudi, Basmah Eldakhakhny, Hussein Sakr, Ayman Elsamanoudy
Summary: It has been found that a low-carbohydrate, high-fat diet can improve dyslipidemia associated with metabolic syndrome. The study results showed that the LCHF diet can lower the levels of Apo B/ApoA1 ratio and TG/HDL ratio, and reduce hepatic steatosis.
Article
Biochemistry & Molecular Biology
Tomohiro Komatsu, Satomi Abe, Shihoko Nakashima, Kei Sasaki, Yasuki Higaki, Keijiro Saku, Shin-ichiro Miura, Yoshinari Uehara
Summary: Sitagliptin phosphate, a DPP-4 inhibitor, increases cholesterol efflux from foam cells and may have anti-atherosclerotic effects independent of glucose metabolism improvements.
Article
Pharmacology & Pharmacy
Sundararajan Mahalingam, Ramesh Bellamkonda, Madan Kumar Arumugam, Sathish Kumar Perumal, Jessica Yoon, Carol Casey, Kusum Kharbanda, Karuna Rasineni
Summary: The GLP-1 receptor agonist exendin-4 has been found to effectively mitigate alcohol-induced hepatic steatosis by regulating fat metabolism, according to an experimental rat model.
BIOCHEMICAL PHARMACOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Khaoula Errafii, Olfa Khalifa, Neyla S. Al-Akl, Abdelilah Arredouani
Summary: No therapy exists for non-alcoholic fatty liver disease (NAFLD). However, glucagon-like peptide receptor agonists (GLP-1RAs) showed a beneficial effect on NAFLD. The study examined the signaling pathways involved in the protective effect of the GLP-1RA Exendin-4 (Ex-4) using comparative transcriptomics in a cell model of steatosis. It identified several key pathways, including FXR/RXR and LXR/RXR, that may contribute to the protective effect of GLP-1RAs on NAFLD.
Article
Endocrinology & Metabolism
Neil Tanday, Andrew English, Ryan A. Lafferty, Peter R. Flatt, Nigel Irwin
Summary: The combined activation of GLP-1 and CCK1 receptors through [Lys(12)Pal]Ex-4/CCK showed enhanced beneficial effects on pancreatic beta-cells, leading to improved insulin secretion and glucose homeostasis in vitro and in mice models. This hybrid peptide therapy also resulted in reductions in energy intake and body weight, as well as improvements in glucose tolerance, insulin responsiveness, and pancreatic islet morphology, highlighting its potential for treating obesity-related diabetes.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Medicine, Research & Experimental
Khaoula Errafii, Neyla S. Al-Akl, Olfa Khalifa, Abdelilah Arredouani
Summary: This study confirmed that Ex-4 can improve steatosis in HepG2 cells and identified 379 and 180 differentially expressed LncRNAs between untreated, steatotic, and Ex-4-treated steatotic cells. Functional enrichment analysis revealed critical pathways involved in fatty acid and pyruvate metabolism, insulin, PPAR, Wnt, TGF-beta, mTOR, VEGF, NOD-like, and Toll-like receptors signaling pathways.
JOURNAL OF TRANSLATIONAL MEDICINE
(2021)
Article
Chemistry, Medicinal
Ali Ismaeil, Fawzi Babiker, Suleiman Al-Sabah
Summary: This study found that GLP-1 (9-36) can protect the heart against ischemia reperfusion injury by normalizing cardiac hemodynamic and enzyme levels, while Ex-4 (9-39) can block the protective effect mediated by Ex-4.
Article
Endocrinology & Metabolism
Kentaro Sakaki, Takaaki Murakami, Hiroyuki Fujimoto, Yoichi Shimizu, Kanae Kawai Miyake, Daisuke Otani, Sakura Kiyobayashi, Takuya Okada, Masakazu Fujimoto, Takuro Hakata, Ichiro Yamauchi, Kotaro Shimada, Hironori Shimizu, Kazuyuki Nagai, Yuji Nakamoto, Nobuya Inagaki
Summary: F-18-exendin-4 PET/CT is a noninvasive diagnostic technique that can help localize insulinomas, and it is crucial for curative surgical resection.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Olfa Khalifa, Khalid Ouararhni, Khaoula Errafii, Nehad M. Alajez, Abdelilah Arredouani
Summary: The study found that the GLP-1RA exendin-4 (Ex-4) can reverse the expression of a set of miRNAs, reducing the occurrence of fatty liver. Enrichment pathway analysis showed that the differentially expressed miRNAs were associated with hepatic fibrosis, insulin receptor, PPAR, Wnt/beta-Catenin, VEGF, mTOR receptor signaling pathways, fibrosis of the liver, cirrhosis of the liver, proliferation of hepatic stellate cells, diabetes mellitus, glucose metabolism disorder, and proliferation of liver cells. These findings suggest that miRNAs may play an important role in the process of reducing fatty liver in response to GLP-1R agonists, which warrants further investigation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Neurosciences
Laura N. Deden, Jan Booij, Joanes Grandjean, Judith R. Homberg, Eric J. Hazebroek, Martin Gotthardt, Marti Boss
Summary: Stimulation of GLP-1 receptors increases insulin release and induces satiety. GLP-1 receptor agonists may have potential benefits for Parkinson's and Alzheimer's diseases, but Ga-68-NODAGA-exendin-4 PET cannot be used to analyze GLP-1 receptors in the brain of obese subjects.
Article
Pharmacology & Pharmacy
Sudhir Pandey, Supachoke Mangmool, Corina T. Madreiter-Sokolowski, Surasak Wichaiyo, Theerut Luangmonkong, Warisara Parichatikanond
Summary: The dysfunction of mitochondria under diabetic condition contributes to the development of neurodegenerative complications. Glucagon-like peptide-1 (GLP-1) receptor agonists have been recognized for their beneficial effects on diabetic neuropathies, but the molecular mechanisms underlying their neuroprotective effects against high glucose-induced neuronal damages are not fully understood.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2023)
Article
Endocrinology & Metabolism
Emilie Steinbach, Davide Masi, Agnes Ribeiro, Patricia Serradas, Tiphaine Le Roy, Karine Clement
Summary: The study of the gut microbiome is crucial for understanding and treating metabolic diseases. While research on the fecal microbiome has provided valuable insights, relying solely on this may not be enough to draw comprehensive conclusions. The microbiome in the proximal part of the small intestine may play a significant role in metabolic regulation, but further exploration is needed due to limited accessibility.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2024)
Article
Endocrinology & Metabolism
Evangelia Chavdoula, Vollter Anastas, Alessandro La Ferlita, Julian Aldana, Giuseppe Carota, Mariarita Spampinato, Burak Soysal, Ilaria Cosentini, Sameer Parashar, Anuvrat Sircar, Giovanni Nigita, Lalit Sehgal, Michael A. Freitas, Philip N. Tsichlis
Summary: This study reveals the important role of KDM2B in triple-negative breast cancer (TNBC). KDM2B affects cellular resistance to oxidative stress by regulating a network of genes and metabolic enzymes, in collaboration with ATF4 and MYC. Additionally, high expression of KDM2B is associated with poor prognosis in patients.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2024)
Article
Endocrinology & Metabolism
Joongmin Kim, Hyeongsoo Kim, Sang Hyun Park, Yura Kang, Kyungdo Han, Sang-Hak Lee
Summary: This study aimed to investigate the optimal LDL-C level after statin therapy in individuals with intermediate cardiovascular risk. The results showed that achieving LDL-C levels <120 mg/dL after statin therapy could lower the event risk.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2024)
Review
Endocrinology & Metabolism
Ze Chen, Li -Ping Xia, Lang Shen, Dan Xu, Yu Guo, Hui Wang
Summary: Accumulating evidence suggests that NAFLD has an intrauterine origin, with adverse prenatal environments and glucocorticoid exposure playing a crucial role in the developmental programming of fetal hepatic lipid metabolism. The offspring's glucocorticoid-insulin-like growth factor 1 (GC-IGF1) axis is programmed in utero, leading to postnatal catch-up growth and disrupted glucose and lipid metabolism, increasing susceptibility to NAFLD. Mismatch between intrauterine and postnatal environments can further disturb the programmed endocrine axes and accelerate the onset of NAFLD.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2024)
Article
Endocrinology & Metabolism
Fuwen Zuo, Youzhao Wang, Xinlei Xu, Ruihao Ding, Wei Tang, Yu Sun, Xiaojie Wang, Yan Zhang, Jichao Wu, Yusheng Xie, Min Liu, Ziying Wang, Fan Yi
Summary: This study investigates the role of CCDC92 in the pathogenesis of diabetic kidney disease (DKD). The expression of CCDC92 was found to increase in kidney biopsies from patients with DKD and was correlated with glomerular lipid accumulation. Animal studies further confirmed the induction of CCDC92 in the kidney, particularly in podocytes, and the podocyte-specific deletion of Ccdc92 ameliorated podocyte injury and lipid deposition. CCDC92 was shown to promote podocyte lipotoxicity through ABCA1 signaling-mediated lipid homeostasis. Therefore, CCDC92 may serve as a potential biomarker of podocyte injury in DKD and targeting CCDC92 could be an innovative therapeutic strategy for DKD patients.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2024)
Review
Endocrinology & Metabolism
Khanyisani Ziqubu, Phiwayinkosi Dludla, Sihle E. Mabhida, Babalwa U. Jack, Susanne Keipert, Martin Jastroch, Sithandiwe E. Mazibuko-Mbeje
Summary: The discovery and revival of brown adipose tissue (BAT) in adult humans have opened up new possibilities for treating obesity and metabolic diseases. BAT not only plays a role in generating heat, but also secretes signaling molecules known as batokines, which regulate overall metabolism. This review highlights the importance of BAT-derived metabolites in controlling thermogenesis, substrate metabolism, and other biological processes, as well as their potential to alleviate obesity and related metabolic complications.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2024)